全球細胞免疫療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

細胞免疫療法市場預計將從 2025 年的 148.7 億美元成長到 2034 年的 935.2 億美元，2026 年至 2034 年的複合年成長率為 22.67%。

由於癌症發病率上升和對標靶治療的需求不斷成長，全球細胞免疫療法市場正經歷顯著成長。 CAR-T細胞療法和先進基因編輯技術的創新正在改變腫瘤治療，並提高患者的存活率。生物技術研究投入的增加、臨床試驗的擴大以及監管部門的核准支持正在加速商業化進程。製藥公司正在加強產能以滿足不斷成長的需求。未來幾年，非腫瘤適應症的拓展和同種異體移植技術的進步預計將推動全球市場持續成長。

骨髓惡性腫瘤和固態腫瘤率的不斷上升仍然是市場成長的主要驅動力。細胞工程和加工技術的進步有助於提高治療效果和安全性。政府和私營機構正在加大對研究舉措的投入，以加速創新。生物技術公司與學術機構之間的策略合作正在加強產品平臺。已開發國家完善的健保報銷機制有助於提高病患的用藥可近性。隨著人們對個人化醫療的認知不斷提高，對客製化免疫療法的需求將持續穩定成長。

精準醫療的日益普及正在改變全球治療模式。細胞處理和生產的自動化有助於降低成本並擴充性。強力的臨床證據表明，持續緩解的療效正在增強醫療服務提供者的信心。生物製藥公司正在投資研發下一代即用型療法，以擴大治療的可及性。新興市場的醫療基礎設施正在逐步完善，創造了新的成長機會。持續的研發和技術改進正在為細胞免疫療法市場的長期永續發展奠定基礎。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球細胞免疫療法市場：依治療方法類型分類

• 市場分析、洞察與預測
• CAR-T細胞療法
• 樹突細胞療法
• NK細胞療法
• TIL療法
• 其他

第5章 全球細胞免疫療法市場：依適應症分類

• 市場分析、洞察與預測
• B細胞惡性腫瘤
• 攝護腺癌
• 肝癌
• 腎臟細胞癌
• 其他

第6章：全球細胞免疫療法市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院
• 癌症研究所
• 其他

第7章 全球細胞免疫療法市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Novartis AG
  • Gilead Sciences Inc.（Kite Pharma）
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • GlaxoSmithKline Plc
  • AstraZeneca
  • Pfizer Inc
  • Johnson & Johnson
  • Celyad
  • Adicet Bio Inc
  • Dendreon Pharmaceuticals LLC

The Cellular Immunotherapy Market size is expected to reach USD 93.52 Billion in 2034 from USD 14.87 Billion (2025) growing at a CAGR of 22.67% during 2026-2034.

The global cellular immunotherapy market is witnessing significant growth due to the rising prevalence of cancer and increasing demand for targeted treatment approaches. Innovations in CAR-T cell therapy and advanced gene-editing technologies are transforming oncology care and improving patient survival rates. Growing investments in biotechnology research, expanding clinical trials, and supportive regulatory approvals are accelerating commercialization. Pharmaceutical companies are enhancing manufacturing capabilities to meet rising demand. In the coming years, expanding indications beyond oncology and advancements in allogeneic therapies are expected to drive sustained market expansion worldwide.

Rising incidences of hematological malignancies and solid tumors remain key drivers of market growth. Technological advancements in cell engineering and processing techniques are improving therapeutic efficacy and safety profiles. Governments and private organizations are increasing funding for research initiatives to accelerate innovation. Strategic collaborations between biotech firms and academic institutions are strengthening product pipelines. Improved reimbursement frameworks in developed countries are enhancing patient access. As awareness of personalized medicine grows, demand for customized immunotherapies will continue to expand steadily.

The increasing focus on precision medicine is reshaping global treatment paradigms. Automation in cell processing and manufacturing is helping reduce costs and improve scalability. Strong clinical evidence demonstrating durable remission benefits is building confidence among healthcare providers. Biopharmaceutical companies are investing in next-generation off-the-shelf therapies to broaden accessibility. Emerging markets are gradually improving healthcare infrastructure, creating new growth opportunities. With continuous research and technological refinement, the cellular immunotherapy market is poised for long-term sustainable development.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy Type

• CAR T Cell Therapy
• Dendritic Cell Therapy
• NK Cell Therapy
• TIL Therapy
• Others

By Indication

• B-cell Malignancies
• Prostate Cancer
• Liver Cancer
• Renal Cell Carcinoma
• Others

By End Use

• Hospitals
• Cancer Institutes
• Others

COMPANIES PROFILED

• BristolMyers Squibb Company, , Novartis AG, Gilead Sciences Inc Kite Pharma, F HoffmannLa Roche Ltd, Merck KGaA, GlaxoSmithKline plc, AstraZeneca, Pfizer Inc, Johnson Johnson, Celyad, Adicet Bio Inc, Dendreon Pharmaceuticals LLC
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. CAR T Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Dendritic Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. NK Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. TIL Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. B-cell Malignancies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Renal Cell Carcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cancer Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CELLULAR IMMUNOTHERAPY MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapy Type
  • 7.2.2 By Indication
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapy Type
  • 7.3.2 By Indication
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapy Type
  • 7.4.2 By Indication
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapy Type
  • 7.5.2 By Indication
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapy Type
  • 7.6.2 By Indication
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CELLULAR IMMUNOTHERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Novartis AG
  • 9.2.2 Gilead Sciences Inc. (Kite Pharma)
  • 9.2.3 F. Hoffmann-La Roche Ltd
  • 9.2.4 Merck KGaA
  • 9.2.5 GlaxoSmithKline Plc
  • 9.2.6 AstraZeneca
  • 9.2.7 Pfizer Inc
  • 9.2.8 Johnson & Johnson
  • 9.2.9 Celyad
  • 9.2.10 Adicet Bio Inc
  • 9.2.11 Dendreon Pharmaceuticals LLC